Full-Time

Director of GMP Procurement & Planning

Multiple Teams

Posted on 2/25/2025

ArsenalBio

ArsenalBio

51-200 employees

Programmable cell therapies for solid tumors

Compensation Overview

$200.1k - $245.1k/yr

Hayward, CA, USA

In Person

Category
Biology & Biotech (4)
, , ,
Requirements
  • Bachelor’s degree or commensurate experience
  • 10 years of GMP sourcing in pharmaceutical or biotech
  • 5 years of people management
  • Pharma/biotech direct material planning experience
  • Strong demonstrated project management capabilities
  • Proficiency with purchasing systems
  • Demonstrated success in managing multiple vendors, including pricing negotiations and alternative vendor sourcing
  • Excellent leadership, collaboration, mentoring, communication, and influencing skills
  • Highly comfortable with fast-paced, rapidly changing environment
Responsibilities
  • Direct and lead the GMP procurement organization covering direct and capital equipment spend. Oversee the order planning and order management functions.
  • Develop the group for phase appropriate readiness and establish procurement strategies.
  • Ensure sufficient GMP raw material inventories to prevent stockouts that delay clinical trial manufacturing
  • Manage the GMP procurement and material planning organization and ensure that the organization is fit-for-purpose to support clinical trials.
  • Develop procurement strategies to continuously improve total costs, service and quality
  • Collaborate closely with Quality, Manufacturing, Product Sciences, and other stakeholders
  • Manage Supplier Relations to address the following: Data review and analysis, performance management, and process improvements; Change notifications, contract initiation, existing contract review, and price negotiations; Develop, implement and manage supplier key performance indicators
  • Research purchasing trends, threats/risks to the supply chain, and develop sourcing and sourcing strategies to mitigate risk to the supply chain and ensure business continuity
  • Develop model for and execute Material Risk Assessment
  • Develop and implement a Material De-risk Program with appropriate strategies: inventory policy, second sources, etc.
  • Manage procurement duties, including: vendor sourcing, request for quote (RFQ) preparation, request for proposals (RFP) purchase order terms and condition negotiation, proposal evaluations, and purchasing of cGMP, equipment, and services
  • Other duties as assigned
Desired Qualifications
  • Cell and gene therapy experience
  • Startup experience
  • Material planning systems experience

ArsenalBio focuses on developing programmable cell therapies to treat solid tumors. Its core work is in the research, development, and clinical testing of therapies that reprogram cells to recognize and attack solid cancers. The product works by engineering cells (likely immune cells or other therapeutic cells) so they can specifically target solid tumor cells and perform its cancer-fighting function once delivered to patients. The company differentiates itself through its emphasis on programmable cell therapies tailored for solid tumors, its clinical-stage status, diverse and cross-disciplinary team, and its end-to-end focus on translating research into commercially available treatments. ArsenalBio’s goal is to bring these therapies to market and generate revenue by delivering approved treatments to healthcare providers to treat patients with solid tumor cancers.

Company Size

51-200

Company Stage

Series C

Total Funding

$630M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • $325M oversubscribed Series C closed September 4, 2024, funds clinical programs.
  • Nate Hardy joined as CFO October 7, 2024, bolstering financial leadership.
  • AB-2100 dosed first patient in Phase 1/2 ccRCC trial using CITE technology.

What critics are saying

  • Bristol Myers Squibb licenses co-developed T-cell programs, sidelining ArsenalBio pipeline.
  • AB-1015 Phase 1 fails efficacy in ovarian cancer from T-cell exhaustion.
  • Cash from $325M Series C burns out post-2026 without Series D funding.

What makes ArsenalBio unique

  • ArsenalBio engineers logic-gated CAR T-cells with dual sensors activating only at tumors.
  • CITE technology integrates transgenes via CRISPR for solid tumor selectivity.
  • Synthetic biology toolkit reprograms T-cells to remodel suppressive microenvironments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

5%

2 year growth

5%
Arsenal Biosciences
Jan 6th, 2025
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

Bakersfield.com
Sep 16th, 2024
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.

William Reed Business Media
Sep 5th, 2024
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies

ArsenalBio bags $325 million to develop crispr-engineered cell therapies.

Arsenal Biosciences
Sep 4th, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development • Arsenal Bio

Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]

CityBiz
Sep 4th, 2024
T. Rowe Price Joins $325 Million Financing for ArsenalBio

T. Rowe Price joins $325 million financing for ArsenalBio.

INACTIVE